Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

- Achieves Record Revenues While Advancing Three Major Clinical Programs and Securing 5-Year Contract With U.S. Defense Threat Reduction Agency

Worth Up to $44.4 Million -

TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced financial results for fiscal year (FY) 2008 ended April 30, 2008. Total revenues for FY 2008 increased 64% to $6,093,000, primarily reflecting increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

Total costs and expenses in FY 2008 increased to $30,233,000 from $25,618,000 in FY 2007. Increased costs of contract manufacturing directly related to the increase in Avid's revenues accounted for almost one-third of the increase in total expenses. Most of the remainder of the increase was due to the company's increased investment in research and development associated with the advancement of its three clinical programs for bavituximab and Cotara(R) for the treatment of solid tumors and hepatitis C virus (HCV) infection. These programs include seven clinical trials: Three bavituximab Phase II studies in combination with chemotherapy for the treatment of advanced breast cancer and non-small cell lung cancer (NSCLC), a bavituximab Phase I cancer study, a bavituximab Phase I study in HCV patients co-infected with HIV, and two Cotara studies for the treatment of glioblastoma multiforme (GBM), a deadly form of brain cancer.

The company reported a consolidated net loss of $23,176,000, or $0.10 per basic and diluted share in FY 2008, compared to a consolidated net loss of $20,796,000, or $0.11 per basic and diluted share for FY 2007.

"This past year has been marked by majo
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 High performance ... apply the most complete climate and Earth system ... climate change issues. , Eight national laboratories, including ... the National Center for Atmospheric Research, four academic ... effort. Other participating national laboratories include Argonne, Brookhaven, ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/20/2014)... August 20, 2014 GraphDB™ ... today including improvements to the enterprise replication cluster, ... for Lucene, SOLR and Elasticsearch. This release happens ... high performance triplestore – GraphDB™ was formerly known ... deploying the only mature enterprise resilient RDF triplestore ...
(Date:8/19/2014)... DANVILLE, Pa. , Aug. 19, 2014 ... C has been nominated for a Centers for Disease ... to addressing a major public health concern. ... Health System, is one of a team of researchers ... (CDC) Charles C. Shepard Science Award for Data Methods ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... Oct. 12, 2011 Neuralstem, Inc. (NYSE Amex: ... allowance from the U.S. Patent and Trademark Office for patent ... Delivering a Therapeutic Agent to a Spinal Cord Target." Neuralstem ... Cleveland Clinic Foundation, where it was developed by Nicholas Boulis, ...
... 2011 Life Technologies Corporation ... Biosystems QuantStudio™ 12K Flex Real-Time PCR system, ... and efficient interrogation of hundreds of target genes over ... The growing demand of biomarker screening experiments, particularly in ...
... 12, 2011 - Two pivotal trials ... ulcerative colitis and Crohn,s disease - Shield ... the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals ... announced that the first patients have been treated in ...
Cached Biology Technology:Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform 2Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform 3Life Technologies Announces Flagship PCR Instrument that Enables Cost-Effective, High-Throughput Screening Applications 2Life Technologies Announces Flagship PCR Instrument that Enables Cost-Effective, High-Throughput Screening Applications 3Life Technologies Announces Flagship PCR Instrument that Enables Cost-Effective, High-Throughput Screening Applications 4Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 2Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 3
(Date:8/20/2014)... years, Virginia Tech,s Wu Feng has built upon a ... "Computing in the Cloud" program, and synergistically complemented it ... from the Air Force on "big computing" for mini-drones ... National Institutes of Health on "big data" for the ... computing" aspects from each grant, he was able to ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
(Date:8/20/2014)... grows to about 4,000 members, it triggers an important ... a special type of comb used for rearing male ... Department of Neurobiology and Behaviour at Cornell University, led ... of honeybee colonies. The results are published in Springer,s ... , Reproduction isn,t always a honeybee colony,s top ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4CU Denver researcher shows economic disparities impact infant health 2Worker bees 'know' when to invest in their reproductive future 2
... NEW YORK -- Water vapor and clouds are the ... atmosphere-ocean climate modeling study shows that the planet,s temperature ... The study, conducted by Andrew Lacis and ... in New York, examined the nature of Earth,s greenhouse ...
... University of British Columbia today welcomed the announcement of ... Health Research (CIHR) and Genome British Columbia for research ... led by UBC researchers Brett Finlay and Deborah Money, ... today in Toronto by federal Health Minister Leona Aglukkaq. ...
... Cancer Research congratulates 12 of its members on their election ... new members and five foreign associates. Considered among ... the award recognizes individuals who have demonstrated outstanding professional achievement ... medicine. "This is a great day for cancer ...
Cached Biology News:Carbon dioxide controls Earth's temperature 2Carbon dioxide controls Earth's temperature 3The AACR congratulates its members elected to the Institute of Medicine 2
Black Polypropylene 384 Round Well Plate 70/Box...
... Rabbit polyclonal to Peroxiredoxin 1 ... peroxidase family, whose mammalian members have ... proliferation, differentiation, and apoptosis. Many isoforms ... to the amino acid sequence homology, ...
... Eliminates nonspecific products due to inactivity ... allows extension through DNA regions which contain ... an 'A' overhang ,TEMPase II is ... Polymerase that remains inactive at room ...
... Synuclein Synucleins are small, soluble proteins ... certain tumors. The family includes three known ... synuclein. The alpha and beta synuclein proteins ... they are seen mainly in presynaptic terminals. ...
Biology Products: